talazoparib
pfizer
['sclc', 'talazoparib']
#asco22 abs #8517 phase 2 study of #talazoparib/tmz in r/r es-sclc by goldman et al. orr: 39.3% mpfs: 4.5 mths mos: 11.9 mths 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own